Meet Robin Foà, our Volunteer of the Month

Can you tell us what you do for EHA and when you started?
I have been a member of EHA from its beginning and have participated in all EHA Congresses.

Meet Robin Foà, our Volunteer of the Month

Can you tell us what you do for EHA and when you started?
I have been a member of EHA from its beginning and have participated in all EHA Congresses.

Immune Therapies for Hematologic Disorders

Recently the treatment of hematological and solid malignancies has been revolutionized by the introduction of novel immunotherapeutic strategies.

Nobel prize goes to immunotherapy researchers

October 1, Sweden - Cancer kills millions of people every year and is one of humanity’s greatest health challenges.

EHA Statement on COVID-19 Vaccines

EHA-Baltic Hematology Tutorial in Estonia provides European-level expertise to local hematologists

EHA partnered with three Baltic societies on October 18 and 19 to provide European-level expertise to local hematology trainees and experienced hematologists.

A new form of inherited thrombocytopenia (ETV6-related thrombocytopenia, ETV6-RT): NEVER JUDGE A BOOK BY ITS COVER!

A new form of inherited thrombocytopenia (ETV6-related thrombocytopenia, ETV6-RT): NEVER JUDGE A BOOK BY ITS COVER!

We recently discovered a new form of an inherited deficiency of platelets (inherited thrombocytopenia-IT), which is caused by mutations in the ETV6-gene.

EHA-RHS-ROHS Hematology Tutorial 2021

EHA in collaboration with the National Hematological Society (RHS) and the Russian Onco-Hematology Society (ROHS) are closely monitoring the developments concerning the Coronavirus (COVID-19), as our priorities lie with the health and safety of our participants and partners.

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.